AstraZeneca buys CDK9 portfolio

AstraZeneca has purchased the CDK9 portfolio of Germany-based Probiodrug AG. The Halle, Germany, biotech announced the deal Thursday, but did not disclose the price tag.

The agreement means AstraZeneca will now own the lead drug and back-up compounds associated with the molecule, which has an impact on genetic transcription connected to inflammation, a condition which is associated with cancer and inflammatory diseases.

You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.